{"id":53452,"date":"2023-01-31T13:02:26","date_gmt":"2023-01-31T12:02:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/"},"modified":"2023-01-31T13:02:26","modified_gmt":"2023-01-31T12:02:26","slug":"enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/","title":{"rendered":"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022"},"content":{"rendered":"<div>\n<p>WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com&amp;esheet=53293638&amp;newsitemid=20230131005112&amp;lan=en-US&amp;anchor=Enanta+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=48aa26747dcd165d43bc766e56d9123c\" rel=\"nofollow noopener\" shape=\"rect\">Enanta Pharmaceuticals, Inc<\/a>. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta\u2019s business, including its research and development pipeline.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230131005112\/en\/1475183\/5\/Enanta_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230131005112\/en\/1475183\/21\/Enanta_RGB.jpg\"><\/a><\/p>\n<p>\n<b>Conference Call and Webcast Information<\/b>\n<\/p>\n<p>\nThe live webcast can be accessed under &#8220;Events &amp; Presentations&#8221; in the investors section of Enanta\u2019s website. To participate by phone, please register for the call <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBI225de771603b46c8a47c780bcd194c31&amp;esheet=53293638&amp;newsitemid=20230131005112&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=8cab56920f5dc3f9cb49dfbe7efa5226\" rel=\"nofollow noopener\" shape=\"rect\">here<\/a>. It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta\u2019s website for approximately 30 days following the event.\n<\/p>\n<p>\n<b>About Enanta Pharmaceuticals, Inc.<\/b>\n<\/p>\n<p>\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta\u2019s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).\n<\/p>\n<p>\nEnanta\u2019s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). Please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.enanta.com&amp;esheet=53293638&amp;newsitemid=20230131005112&amp;lan=en-US&amp;anchor=www.enanta.com&amp;index=3&amp;md5=88d9481c6c23768ca4bc16dfda8332fe\" rel=\"nofollow noopener\" shape=\"rect\">www.enanta.com<\/a> for more information.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media and Investor Contact<\/b><br \/>Jennifer Viera<br \/>\n<br \/>617-744-3848<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;o&#x3a;j&#x76;&#105;&#x65;&#114;&#x61;&#64;&#x65;&#110;a&#110;t&#x61;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">j&#118;&#105;&#x65;&#x72;a&#64;&#101;&#x6e;&#x61;&#x6e;t&#97;&#46;&#x63;&#x6f;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023. Enanta management will host a conference call &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53452","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023. Enanta management will host a conference call ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-31T12:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230131005112\/en\/1475183\/21\/Enanta_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022\",\"datePublished\":\"2023-01-31T12:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/\"},\"wordCount\":331,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005112\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/\",\"name\":\"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005112\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"datePublished\":\"2023-01-31T12:02:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005112\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005112\\\/en\\\/1475183\\\/21\\\/Enanta_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 - Pharma Trend","og_description":"WATERTOWN, Mass.&#8211;(BUSINESS WIRE)&#8211;Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023. Enanta management will host a conference call ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-31T12:02:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230131005112\/en\/1475183\/21\/Enanta_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022","datePublished":"2023-01-31T12:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/"},"wordCount":331,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005112\/en\/1475183\/21\/Enanta_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/","url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/","name":"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005112\/en\/1475183\/21\/Enanta_RGB.jpg","datePublished":"2023-01-31T12:02:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230131005112\/en\/1475183\/21\/Enanta_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230131005112\/en\/1475183\/21\/Enanta_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-host-conference-call-on-february-7-at-430-p-m-et-to-discuss-its-financial-results-for-its-fiscal-first-quarter-ended-december-31-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53452"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53452\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}